Therapeutic Classification: vaccines/immunizing agents
Pharmacologic Classification: immune globulins, monoclonal antibodies
Absorption: 84% absorbed following IM administration.
Distribution: Not widely distributed to tissues.
Metabolism/Excretion: Degraded into small peptides by catabolic pathways.
Half-Life: 71 days.
(neutralizing antibody plasma concentrations)
| ROUTE | ONSET | PEAK | DURATION |
|---|
| IM | unknown | 6 days | unknown |
Neonates and Infants Born During or Entering Their First RSV Season
- IM (Neonates and Infants <8 mo and ≥5 kg): 100 mg as single dose; Undergoing cardiac surgery with cardiopulmonary bypass (>90 days since initial dose): Administer additional 50 mg as single dose; Undergoing cardiac surgery with cardiopulmonary bypass (≤90 days since initial dose): Administer additional 100 mg as single dose.
- IM (Neonates and Infants <8 mo and <5 kg): 50 mg as single dose. Undergoing cardiac surgery with cardiopulmonary bypass (regardless of time since initial dose): Administer additional 50 mg as single dose.
Children Who Remain at Increased Risk for Severe RSV Disease in Their Second RSV Season
- IM (Infants and Children 8–19 mo): 200 mg as a single dose. Undergoing cardiac surgery with cardiopulmonary bypass (>90 days since initial dose): Administer additional 100 mg as single dose; Undergoing cardiac surgery with cardiopulmonary bypass (≤90 days since initial dose): Administer additional 200 mg as single dose.
